Boehringer Ingelheim Biopharmaceuticals (China) Ltd.
EIR issued June 9, 2023
- Investigator
- Leiyun Boone
- Pages
- 85
- FEI number
- 3015009021
In short: This is FDA's Establishment Inspection Report (EIR) for Boehringer Ingelheim Biopharmaceuticals (China) Ltd. (FEI 3015009021). It is the investigator's full narrative of what they examined, who they spoke to and what they found. The investigator was Leiyun Boone.
Inside this inspection report
The investigator's narrative
The full inspection report: what the investigator looked at, who they spoke to and what they found, in their own words.
Get the full EIRThis inspection in context
Leiyun Boone
8 documents · 2021–2025
Cites 211.113 (control of microbiological contamination) more than any other section. Most of their documents are for sites in Germany.
The firmBoehringer Ingelheim Biopharmaceuticals (China) Ltd. history
All 2 documents on file for this site, in date order, with what was cited at each inspection.
Similar documentsMore eirs
Browse other documents of this type.
Questions about this EIR
Who inspected Boehringer Ingelheim Biopharmaceuticals (China) Ltd.?
Leiyun Boone is named on this EIR. Each investigator has a profile showing what they cite most.
When was Boehringer Ingelheim Biopharmaceuticals (China) Ltd. inspected by FDA?
This EIR is dated June 9, 2023.
How do I get the full EIR for Boehringer Ingelheim Biopharmaceuticals (China) Ltd.?
Download the original PDF from FDA Intel for $550, with no subscription. You also get an invoice PDF with the order.